A recent study reported that targeting LncRNA H19 can reverse pathological cardiac hypertrophy by interacting with polycomb repressive complex 2 (PRC2) to control the nuclear factor of activated T-cells (NFAT) signaling [21]. This evidence concerns the gene H19 and cardiac hypertrophy.